Splenic B lymphocytes specifically reactive to the hapten fluorescein (FLU) were prepared from nonimmune adult mice by affinity fractionation on hapten-gelatin. These FLU-specific B cells were cultured as single cells or in small numbers in 10-ul wells either in the absence of any feeder, filler, or accessory cell or in the presence of 3T3 fibroblasts acting as filer cells. A selected batch ofa "T-cell-independent" antigen, FLU-Ficoll, which induces growth and differentiation only in the presence of lymphokines or cytokines acting as B-cell growth and differentiation factors (BGDF), was used as the antigenic stimulus. It was found that murine interleukin 1 prepared by recombinant DNA technology was an effective, although weak, BGDF when acting with antigen on B cells cultured either under filler cell-free conditions or in the presence of 3T3 cells. When the murine interleukin 1 was used in combination with recombinant human interleukin 2, itself a weak but effective BGDF in the system, an additive effect was observed. The results challenge the notion that interleukin 1 is exclusively or even primarily an activating cytokine. This system, in which pure factors are able to act with specific antigen on single hapten-specific B cells, will prove helpful for the further dissection of the respective roles of the various factors that can act on B cells.
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The important macrophage-derived growth-regulatory molecule interleukin 1 (IL-1) (1) has recently been produced in pure form through recombinant DNA technology (2) . Ever since the description of IL-1 as a lymphocyte-activating factor (3, 4) , its bioactivity has been assumed to relate primarily if not exclusively to early events in the activation of a resting, Go, cell. For example, IL-1 is seen as a cofactor required for concanavalin A to exert its activating effects on T lymphocytes (5) with concomitant expression of IL-2 receptors, after which IL-2 is seen as the only growth factor required for further proliferation of the T-cell clone. IL-1 has also been implicated in the activation of B lymphocytes (6) (7) (8) (9) (10) , though in this instance, some work has suggested that it acts later than another postulated activating factor, B-cellstimulating factor 1 (BSF-1) (6) .
We have reported (11) (12) (13) (14) a system in which normal murine B lymphocytes, preselected on the basis of their antigen specificity, are able to be stimulated to proliferate and differentiate to immunoglobulin secretion status when cultured singly in the presence of antigen and a source of B-cell growth and differentiation factors (BGDF). Under these conditions, the B cell itself is the only possible target for the action of antigen and factors. In the belief that this system was ideal for testing various purified factors for bioactivity on B cells, we have used it to assess the bioactivity of murine IL-1, prepared by recombinant DNA technology (r-mu-IL-1). The results show IL-1 to have a combination of bioactivities, including the promotion of both growth and differentiation of B cells. Moreover, when filler cells were added to the single B cell, the bioactivities exhibited by IL-1 were identical to those in the filler cell-free system.
MATERIALS AND METHODS
Mice and Preparation of Fluorescein (FLU)-Specific Splenic B Cells. Specific-pathogen-free CBA/CaH/Wehi mice were used as spleen donors at 8-10 weeks of age. Hapten-specific B-cell populations were prepared from spleen cell suspensions by fractionation on FLU-gelatin as described (15) (16) (17) . Adherent FLU-gelatin was removed from the recovered binding cells by collagenase. The binding population is 97% B cells, -z70% FLU-binding, and -200-fold enriched for in vitro reactivity to FLU conjugates (13, 16, 17) .
Antigen. The hapten FLU was coupled onto aminoethylcarbonylmethylated Ficoll (AECM53-Ficoll), as described (16, 17) , and the FLU53-Ficoll was used as a final concentration of 0.1 ng/ml. EL4 Thymoma Cell-Derived BGDF. A lOx concentrate of medium conditioned by concanavalin A-stimulated EL4 thymoma cells prepared as described (12) was used as a source ofT-cell-derived BGDF at a final concentration of 5% (vol/vol). According to the recently proposed convention (18) this is termed EL-BGDF-pik.
Recombinant Murine IL-1 (r-mu-IL-1). The r-mu-IL-1 was prepared as described (2) and kindly provided by Hoffmann-La Roche (lot 11319-229-48). The concentration of r-mu-IL-1 is expressed as units/ml of IL-1 activity as determined by the providers, using the thymocyte proliferation assay (19) .
Recombinant Human IL-2 (r-hu-IL-2). The r-hu-IL-2 was prepared as described (20) and kindly provided by Cetus Immune (Palo Alto, CA) (lot LP-222). Activity is expressed as units/ml of r-hu-IL-2 as determined by using a murine CTL-L line as described (21 BALB/c 3T3 fibroblast cells as described (13, 14, 17) . For some purposes-e.g., the delineation of factor concentration-response characteristics-an oligoclonal approach using a mean of 10 B cells per well was used as described (14) . The additional presence of filler cells markedly improves both cloning efficiency and clone size (13, 14, 17 
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conditions, a further 5 ul of medium alone was added. Factors were added in a further 1 /.l of medium at lix the required final concentration.
Assessment of Clonal Proliferation. Before assay for antibody formation, culture wells were examined, by using an inverted phase microscope as described (12, 13, 17) , for the presence or absence of a proliferating B-cell clone. In the presence of 3T3 cells, the proliferating B cells could usually be distinguished, due to the adherence to plastic, the different morphology, and the substantially larger size of the 3T3 cells.
Assessment of Antibody Formation. Antibody formation was assessed by using a sensitive enzyme-linked immunosorbent assay (ELISA) procedure as described (14) . As the target B cells were selected for specificity for FLU by prefractionation on hapten-gelatin, a sheep anti-murine immunoglobulin antibody (SAM) was used as the polyvalent antigen in the ELISA assay rather than FLU coupled to bovine serum albumin. This change was to measure antibody production per se, regardless of its affinity, as a result of particular stimuli. Briefly, the supernatant fluid of each culture well was individually transferred into the wells of a 96-well flexible U-bottomed polyvinyl plate (Dynatech, Alexandria, VA) precoated with affinity-purified SAM (Silenus Laboratories, Dandenong, Australia) at 3 ,ug/ml and containing 50 /.l of 0.3% skim milk powder and 0.05% Tween 20 in phosphate-buffered saline. After a period of >2 hr at room temperature, the plates were washed in PBS-tween 20 and horseradish peroxidase-coupled SAM was added for a period of >4 hr. After washing, the substrate 2,2'-azinobis(3-ethylbenzthiazolinesulfonic acid) (ABTS) (Sigma) was added and the absorbance of the fluid in the wells was read 1 hr later with a Titertek Multiscan ML (Flow Laboratories) using dual wavelengths (414 and 492 nm). A well was considered positive if its absorbance exceeded the mean ± 3 SEM of the background as calculated on the basis of a large number of replicates of supernatants from wells lacking B-cell input. Control wells lacking antibody consistently gave an absorbance value of <0.010 unit. The frequency of antibodyforming cell (AFC) clone precursors was determined by Poisson analysis as described (12) (13) (14) (15) 22) . Data for supernatants from wells of oligoclonal cultures are expressed as the mean ± SEM of the absorbance of 12 replicate wells.
RESULTS

Synergy of IL-1 and Antigen in Promotion of AFC Clone
Formation by Single Hapten-Specific B Cells in the Presence of 3T3 Filler Cells. Fig. 1 shows a typical limiting dilution analysis in which various numbers of FLU-specific B cells were stimulated with FLU-Ficoll plus EL-BGDF-pik (Fig.  lA) or FLU-Ficoll in the absence and presence of r-mu-IL-1 at 100 units/ml (Fig. 1B) . While r-mu-IL-1 was clearly not as strong a BGDF as the mixture of lymphokines contained within EL-BGDF-pik, a significant elevation of AFC clone frequency was seen when both antigen and IL-1 were present, as opposed to antigen alone. Furthermore, the response followed the expected Poisson distribution, indicating that only the responder B cells are limiting in the system. Thus IL-1 can synergize with antigen to promote AFC clone development from single B cells. Proliferation as observed by microscopic visualization correlated with AFC clone formation (data not shown). The dose-response characteristics of the BGDF activity of r-mu-IL-1 are shown in Table 1 . Preliminary screening was performed under oligoclonal conditions, using an average of 10 FLU-specific B cells per well, then the findings were confirmed by clonal analysis. With clonal analysis, a flat dose-response relationship was noted, whereas oligoclonal analysis showed a modest increase in the amount of antibody with r-mu-IL-1 at 100 units/ml. In both systems, r-mu-IL-1 exhibited weak but definite BGDF activity, its addition raising the cloning efficiency and final antibody amount above background, but only to about one-quarter the level of EL-BGDF-pik. The relative effects are further illustrated by Table 2 , which shows the pooled results of eight experiments in which antibody formation with FLU-Ficoll alone, FLU-Ficoll plus r-mu-IL-1 at 100 units/ml, and FLU-Ficoll plus EL-BGDFpik were directly compared. The results confirm the data of Table 1 and add the further point that the amount of antibody formed in the presence of factors is greater than that of the occasional clones arising in their absence. r-mu-IL-1 was 100 units/ml when present. Values represent mean ± SEM of eight directly comparative experiments. Highly significant elevation of the response to antigen alone was seen by the further addition of either IL-1 or EL-BGDF-pik. The response to antigen plus EL-BGDF-pik was significantly greater than that ofantigen plus r-mu-IL-1 (P < 0.025). *Determined by Student's t test and representing difference from response with antigen alone.
BGDF Activity of r-mu-IL-l Acting with Antigen on Single
Hapten-Specific B Cells in the Absence of Filler Cells. The ability of IL-1 to act as a BGDF on single hapten-specific B cells stimulated with specific antigen in the absence of fillers or any other cell type was investigated. FLU-specific B cells were stimulated with FLU-Ficoll and various concentrations of r-mu-IL-i. Both oligoclonal and clonal analyses were performed ( Table 3) .
As expected, far fewer AFC clones developed in the absence offillers, and the absorbance values were also lower. Dose-response analysis showed that 10 or 100 units/ml had significant BGDF activity. One unit/ml was clearly suboptimal and 1000 units/ml was clearly supra-optimal, in contrast with the rather flat dose-response relationship in the presence of fillers ( (14, 21) when acting under either filler cell-free (21) or 3T3 cellsupported conditions (14) . It has been reported that exposure to IL-1 is a prerequisite for T lymphocytes to be able to respond to IL-2 (5). Furthermore, it has been proposed that resting B cells require a similar signal from IL-1 before they are able effectively to respond to BGDF (7, 8) . The possibility that IL-1 and IL-2 may exhibit some synergy in their action on B lymphocytes was therefore investigated. FLU-specific B cells were stimulated with antigen in the absence of added factors, or with 100 units/ml of either r-mu-IL-1 or r-hu-IL-2, or both, and the AFC clone frequency was determined by ELISA after 5-6 days. Rather than a synergistic effect, an additive effect was achieved by the addition ofboth cytokines (Table 4) . Furthermore, and somewhat surprisingly, the amount of antibody formed per clone was not significantly greater when both lymphokines were present. No difference in the response was noted when the addition of the IL-2 was 
DISCUSSION
The results presented in this paper have clearly shown that a soluble macrophage-derived factor, IL-1, prepared by recombinant DNA technology, can act in synergy with specific antigen to promote growth and differentiation amongst single, isolated hapten-specific B cells and can do so in the absence of any other lymphokine or any other cell. This result stands in contrast to the concept of IL-1 as purely an "activating" cytokine.
While no consensus exists about the respective roles ofthe various growth factors capable of affecting B lymphocytes (6) (7) (8) (9) (10) (23) (24) (25) (26) (27) (28) (29) (30) (31) , much of the literature on "T-independent" B-cell activation (e.g., ref. 8 ) supports a scheme shown in Fig. 2A . A small, resting B cell is seen as being activated from its Go state by the conjoint action of multivalent antigen (or anti-p heavy chain antibody) and an activation factor, seen by some as an IL-1-like molecule (8) or by others as a particular T-cell-derived lymphokine [e.g., BSF-1 (27, 29) ]. This activated B cell displays an increased amount of surface Ia antigens (30) (31) (32) , an increased amount of RNA and protein synthesis (30, 32, 33) , and a slight increase in size (30, 33) . Its activated state is referred to as the Go or GlA (33) growth state. At this stage, the cell is postulated to display receptors for one or more B-cell growth factors, which drive the cell into active cycle. After an undefined number of divisions, the cells are postulated to display receptors for one or more differentiation factors, which encourage differentiation towards active secretory status (6, 8, (23) (24) (25) (26) 29) .
While much effort has gone into the purification of factors based on assay systems that seek to force each factor into one of these three conceptual categories, each acting at a specific stage in the differentiation pathway, the model has not gone unchallenged. Thus, it has recently been claimed that BSF-1 (formerly termed BSF-pl and before that BCGF-I) is not primarily a growth factor but rather is an activation factor (27, 29) . Furthermore, recent evidence (34) suggests that B-cell growth factor II (BCGF-II) (28) can promote both growth and secretion among activated B cells. Similarly, the believed differentiation factor from the hybridoma B151K12 (26) now appears to have characteristics very similar to BCGF-II (35) . Our own studies using single hapten-specific B cells, reinforced by the present study, do not support the current scheme as shown in Fig. 2A . Rather, the data demonstrate that a single factor has all three of the claimed activities:
promotion of the Go to G1 transition, promotion of cell division, and promotion of differentiation to secretory status (12-14, 17, 21) . We therefore propose an alternative scheme of "T-independent" activation as outlined in Fig. 2B . We suggest the possibility that any one of several factors/ cytokines can promote the full sequence (though perhaps only on particular subsets of B cells). This is clear for IL-2 (21), IL-1 (present paper, ref. 9), gel filtration and chromatographic fractions of EL-BGDF-pik (12) , and also highly purified human BCGF-II and B-cell differentiation factor (BCDF) (reviewed in refs. 24 and 25) kindly provided by T. Kishimoto (data not shown). A possible heterogeneity among B cells is suggested by the findings that the frequency of clones generated with optimal amounts of either IL-1 or IL-2 is lower than that found when both were used (Table 4) , in which case an additive effect was noted. More direct investigation of B-cell heterogeneity in factor responsiveness will soon be feasible. This will require purification of all relevant B cell-active factors, perhaps five or more; identification of respective cellular receptors, and development of anti-receptor monoclonal antibodies, combined with multiparameter cell sorter analysis and appropriate clonal assays.
In contrast to claims for T-cell activation (5), preliminary kinetic studies did not favor the view that prior exposure of cells to antigen plus IL-1 increases the response to IL-2 in the single-cell system. The question of increased IL-2 receptor expression remains to be explored.
If IL-1 were predominantly an activating factor helping B cells to move from Go to G1, one might anticipate that it would exert its maximum effects on small B lymphocytes and be less effective on large B cells. We have reported (13) that B cells slightly larger than median yield the highest cloning frequency when EL-BGDF-pik is used as a factor source. This poor responsiveness of small B cells could be due to the absence of an IL-1-like activating factor in the EL-BGDFpik. Preliminary data (not shown) argue against this explanation. The addition of optimal amounts of IL-1 does not augment the EL-BGDF-pik response. Furthermore, the response oflarge cells to FLU-Ficoll and IL-1 far exceeded that of small cells, although the proportionate increase above the "antigen alone" background was somewhat greater for the small cells. The capacity of IL-1 to enhance the performance of large cells certainly substantiates that it is more than just a cycle-initiating monokine.
The finding that IL-1 can act with antigen to promote activation, division, and differentiation of B cells was surprising, and it suggests that all claims for factor synergies should really be confirmed in a system in which a single B cell is the unequivocal target of factor action. So far, no mixture of pure lymphokines has been as effective in our hands as EL-BGDF-pik. It thus remains a challenge to explore possible synergistic interactions between factors, which can be done at the level of the single B cell as more pure molecules become available.
